Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

NVSNovartis PharmaceuticalsFinished

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Hypertension

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due May 2025, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 3
Patients
718 (final count)
Started
Apr 8, 2024
Main results expected
May 28, 2025
Fully finished
Dec 23, 2025
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • [Core Part] Change from baseline to Week 8 in msSBP

    Measured over: Baseline, Week 8

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-05-28, no fading

Raw record changes

  • none yet

Trial ID NCT06236061 · record last updated 2026-01-13 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06236061) ↗